145102 20260217205557.0 doi 10.1159/000539504 sideral 139888 ART-2024-139888 eng Bambó, María Pilar A four-years retrospective study: Clinical outcomes of XEN45 in patients with glaucoma 2024 Access copy available to the general public Unrestricted Introduction: To evaluate the long-term effectiveness and safety of XEN45 implant, either alone or in combination with cataract surgery, in patients with glaucoma. Methods: Retrospective and single center study conducted on consecutive patients who underwent a XEN45 implant, either alone or in combination with cataract surgery, between November 2016 and October 2021. The primary endpoint was the mean IOP lowering from preoperative values. Results: Among the 230 screened patients, 206 eyes (176 patients) were included. Fifty-three (25.7%) eyes had undergone XEN-alone and 153 (74.3%) eyes had undergone a combined procedure (XEN+Phacoemulsification). The mean preoperative intraocular pressure (IOP) was significantly higher in the XEN-alone (22.2±5.9 mmHg) than in the XEN+Phaco (19.8±4.5 mmHg) group (p=0.0035). In the overall study population, the mean preoperative IOP was significantly lowered from 20.5±5.0 mmHg to 15.8±4.4 at year-4, p<0.0001. The mean preoperative (95% CI) IOP was significantly lowered from 22.2 (20.6 to 23.8) mmHg and 19.8 (19.1 to 20.6) mmHg to 15.6 (12.2 to 16.9) mmHg and 15.9 (15.2 to 16.5) mmHg at year-4 in the XEN-alone and XEN+Phaco groups, respectively (p<0.0001 each, respectively). The number of ocular hypotensive medications was significant reduced from 2.6±1.0 drugs to 1.3±1.3 drugs, with no significant differences between XEN-alone and XEN+Phaco groups (p=0.1671). On the first postoperative day, 62 (30.1%) eyes presented some type of complication. Fifteen (7.3%) eyes underwent a needling procedure. Conclusion: XEN45, either alone or in combination with phacoemulsification, significantly lowered the IOP and reduce the need of ocular hypotensive medication in the long-term. info:eu-repo/semantics/openAccess by https://creativecommons.org/licenses/by/4.0/deed.es 1.9 2024 OPHTHALMOLOGY 47 / 99 = 0.475 2024 Q2 T2 0.814 2024 Medicine (miscellaneous) 2024 Q2 Sensory Systems 2024 Q2 Ophthalmology 2024 Q2 Cellular and Molecular Neuroscience 2024 Q3 4.7 2024 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Tello, Álvaro Vicente, María José Universidad de Zaragoza Mallén, Víctor Universidad de Zaragoza Biescas-Merino, Andrés Yáñez, Jacobo Isanta, Carlos Universidad de Zaragoza (orcid)0000-0003-0558-065X Ferrández, Blanca Fuentemilla, Enrique Pérez-Oliván, Susana Güerri, Noemí Universidad de Zaragoza (orcid)0000-0001-8563-3437 Larrosa, José Manuel Universidad de Zaragoza (orcid)0000-0002-6745-7668 Polo, Vicente Universidad de Zaragoza (orcid)0000-0002-1402-3129 Pablo, Luis Emilio Universidad de Zaragoza (orcid)0000-0003-2389-8282 1007 610 Universidad de Zaragoza Dpto. Medicina, Psiqu. y Derm. Area Medicina 1013 646 Universidad de Zaragoza Dpto. Cirugía Área Oftalmología 1013 817 Universidad de Zaragoza Dpto. Cirugía Área Urología 67 (2024), 478–487 Ophthalmic res. OPHTHALMIC RESEARCH 0030-3747 440342 http://zaguan.unizar.es/record/145102/files/texto_completo.pdf Versión publicada 1988899 http://zaguan.unizar.es/record/145102/files/texto_completo.jpg?subformat=icon icon Versión publicada oai:zaguan.unizar.es:145102 articulos driver 2026-02-17-20:43:18 ARTICLE